» Articles » PMID: 25845862

Ceftazidime-avibactam Activity Tested Against Enterobacteriaceae Isolates from U.S. Hospitals (2011 to 2013) and Characterization of β-lactamase-producing Strains

Overview
Specialty Pharmacology
Date 2015 Apr 8
PMID 25845862
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Ceftazidime-avibactam (MIC50/90, 0.12/0.25 μg/ml) inhibited 99.9% (20,698/20,709) of Enterobacteriaceae isolates at ≤8 μg/ml. This compound was active against resistant subsets, including ceftazidime-nonsusceptible Enterobacter cloacae (MIC50/90, 0.25/0.5 μg/ml) and extended-spectrum β-lactamase (ESBL) phenotype isolates. An ESBL phenotype was noted among 12.4% (1,696/13,692 isolates from targeted species) of the isolates, including 776 Escherichia coli (12.0% for this species; MIC50/90, 0.12/0.25 μg/ml), 721 Klebsiella pneumoniae (16.3%; MIC50/90, 0.12/0.25 μg/ml), 119 Klebsiella oxytoca (10.3%; MIC50/90, 0.06/0.25 μg/ml), and 80 Proteus mirabilis (4.9%; MIC50/90, 0.06/0.12 μg/ml) isolates. The most common enzymes detected among ESBL phenotype isolates from 2013 (n = 743) screened using a microarray-based assay were CTX-M-15-like (n = 307), KPC (n = 120), SHV ESBLs (n = 118), and CTX-M-14-like (n = 110). KPC producers were highly resistant to comparators, and ceftazidime-avibactam (MIC50/90, 0.5/2 μg/ml) and tigecycline (MIC50/90, 0.5/1 μg/ml; 98.3% susceptible) were the most active agents against these strains. Meropenem (MIC50/90, ≤0.06/≤0.06 μg/ml) and ceftazidime-avibactam (MIC50/90, 0.12/0.25 μg/ml) were active against CTX-M-producing isolates. Other enzymes were also observed, and ceftazidime-avibactam displayed good activity against the isolates producing less common enzymes. Among 11 isolates displaying ceftazidime-avibactam MIC values of >8 μg/ml, three were K. pneumoniae strains producing metallo-β-lactamases (all ceftazidime-avibactam MICs, >32 μg/ml), with two NDM-1 producers and one K. pneumoniae strain carrying the bla(KPC-2) and bla(VIM-4) genes. Therapeutic options for isolates producing β-lactamases may be limited, and ceftazidime-avibactam, which displayed good activity against strains, including those producing KPC enzymes, merits further study in infections where such organisms occur.

Citing Articles

Rationale and Logistics of Continuous Infusion Cephalosporin Antibiotics.

Blunier A, Crocker R, Foster R, May S, Powers C, Bookstaver P Pharmacy (Basel). 2024; 12(6).

PMID: 39728850 PMC: 11678214. DOI: 10.3390/pharmacy12060185.


Extended-spectrum β-lactamase-producing from poultry: A review.

Widodo A, Khairullah A, Effendi M, Moses I, Agustin A Vet World. 2024; 17(9):2017-2027.

PMID: 39507773 PMC: 11536724. DOI: 10.14202/vetworld.2024.2017-2027.


Crystal structure of the class A extended-spectrum β-lactamase CTX-M-96 in complex with relebactam at 1.03 Angstrom resolution.

Ghiglione B, Rodriguez M, Penzotti P, Bethel C, Gutkind G, Bonomo R Antimicrob Agents Chemother. 2024; 68(8):e0172123.

PMID: 38990013 PMC: 11304709. DOI: 10.1128/aac.01721-23.


Activities of aztreonam in combination with several novel β-lactam-β-lactamase inhibitor combinations against carbapenem-resistant strains coproducing KPC and NDM.

Li X, Zhang J, Wang J, Long W, Liang X, Yang Y Front Microbiol. 2024; 15:1210313.

PMID: 38505552 PMC: 10949892. DOI: 10.3389/fmicb.2024.1210313.


Cephalosporin resistance, tolerance, and approaches to improve their activities.

Araten A, Brooks R, Choi S, Esguerra L, Savchyn D, Wu E J Antibiot (Tokyo). 2023; 77(3):135-146.

PMID: 38114565 DOI: 10.1038/s41429-023-00687-y.


References
1.
Kaiser R, Castanheira M, Jones R, Tenover F, Lynfield R . Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007-2009 SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2013; 76(3):356-60. DOI: 10.1016/j.diagmicrobio.2013.03.032. View

2.
Shlaes D . New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci. 2013; 1277:105-14. DOI: 10.1111/nyas.12010. View

3.
Tacconelli E, Cataldo M, Dancer S, de Angelis G, Falcone M, Frank U . ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2013; 20 Suppl 1:1-55. DOI: 10.1111/1469-0691.12427. View

4.
Schwaber M, Carmeli Y . Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007; 60(5):913-20. DOI: 10.1093/jac/dkm318. View

5.
Lee C, Doi Y . Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens. Infect Chemother. 2014; 46(3):149-64. PMC: 4189141. DOI: 10.3947/ic.2014.46.3.149. View